Twist Bioscience CORP 8-K filings

Twist Bioscience Corporation announced the pricing of an upsized public offering of 3,125,000 shares of common stock at $96.00 per share, raising approximately $300 million in gross proceeds.

Twist Bioscience announced record revenue of $118.4 million for its fiscal third quarter of 2026, a 23% increase year-over-year, and raised its full-year revenue guidance.

Twist Bioscience announced record revenue of $110.7 million for its fiscal second quarter of 2026, a 19% increase year-over-year, and raised its full-year revenue guidance.

Twist Bioscience Corporation will issue 632,328 shares and $5 million cash to acquire a license, technology, and a 6% ownership stake in Invenra Inc., securing a board seat.

Twist Bioscience Corporation announced the results of its 2026 Annual Meeting, where shareholders re-elected three Class II Directors, approved executive compensation, and ratified Ernst & Young LLP as its independent auditor.

Twist Bioscience reported record first-quarter fiscal 2026 revenue of $103.7 million, a 17% increase year-over-year, and raised its full fiscal year 2026 revenue guidance.

Twist Bioscience reported preliminary first quarter fiscal 2026 revenue of $103.7 million, surpassing its own guidance and growing 17% year-over-year.

Twist Bioscience reported record revenues for fiscal year 2025 and the fourth quarter, alongside significant gross margin improvement and a clear path to adjusted EBITDA breakeven in fiscal 2026.

Twist Bioscience Corporation announced the appointment of Trynka Shineman Blake, former Vistaprint CEO, to its Board of Directors and Audit Committee.

Twist Bioscience announced record third-quarter fiscal 2025 revenue of $96.1 million and achieved net income of $20.4 million, significantly improving profitability and raising full-year guidance.

Twist Bioscience spun out its DNA data storage division into Atlas Data Storage, securing $155 million in funding, while also reporting a 23% increase in Q2 revenue and raising full-year guidance.

Twist Bioscience Corporation's stockholders approved key proposals at the 2025 Annual Meeting, including amendments to the equity incentive plan and corporate charter.

Twist Bioscience achieved record revenue of $88.7 million in the first quarter of fiscal year 2025, marking an increase of 24% year-over-year and the eighth consecutive quarter of sequential growth.

Twist Bioscience announced record full-year revenue of $313.0 million for fiscal year 2024, a 28% increase year-over-year, and exceeded its financial guidance.

Twist Bioscience has entered into a month-to-month consulting agreement with former executive James Thorburn following the expiration of his employment agreement.

Twist Bioscience reported record revenue of $81.5 million for the third quarter of fiscal year 2024, surpassing previous guidance and increasing its full-year revenue outlook.

Twist Bioscience announced a 25% increase in revenue and a 45% increase in orders for the second quarter of fiscal year 2024, along with an improved full-year outlook.

Twist Bioscience held its 2024 Annual Meeting, where stockholders elected two directors, approved executive compensation, and ratified the appointment of Ernst & Young LLP as the independent auditor.

Twist Bioscience announced record revenue of $71.5 million for the first quarter of fiscal year 2024, a 32% increase year-over-year, and raised its full-year revenue and gross margin guidance.